Genetic Technologies Limited (GTG.AX)
- Previous Close
0.1750 - Open
0.1350 - Bid 0.1350 x 10000000
- Ask 0.1450 x 249000000
- Day's Range
0.1300 - 0.1450 - 52 Week Range
0.0930 - 0.1850 - Volume
395,611 - Avg. Volume
65,979 - Market Cap (intraday)
19.621M - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
genetype.comRecent News: GTG.AX
Performance Overview: GTG.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GTG.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GTG.AX
Valuation Measures
Market Cap
16.16M
Enterprise Value
12.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.86
Price/Book (mrq)
3.36
Enterprise Value/Revenue
1.51
Enterprise Value/EBITDA
-1.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-124.08%
Return on Assets (ttm)
-52.71%
Return on Equity (ttm)
-160.47%
Revenue (ttm)
10.24M
Net Income Avi to Common (ttm)
-12.71M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.73M
Total Debt/Equity (mrq)
7.95%
Levered Free Cash Flow (ttm)
-4.6M